Year Founded
1998
Ownership
Public
Employees
~80
Stage
Phase 3
Modalities
Small molecule

Speedel General Information

Lead compound SPP100 (aliskiren) completed Phase 3 trials for hypertension with Novartis. Several other compounds in development including SPP301 (avosentan) completed Phase 2.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Basel,
Switzerland

Drug Pipeline

aliskiren
Phase 3
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Speedel's pipeline data

Book a demo

Key Partnerships

Novartis, Roche, Locus Pharmaceuticals

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Speedel Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Speedel's complete valuation and funding history, request access »

Speedel Investors

Novartis (initial funding in 1998)
Investor Type: Venture Capital
Holding: Minority